Crizanlizumab clinical trials
Crizanlizumab is named as an intervention in 4 current clinical trials in our USA, Brazil, Germany, France, Spain, Italy, Belgium, Turkey, UK, India, Netherlands, Canada and Israel registers. 3 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Novartis Pharmaceuticals (3). The most-studied condition is Sickle Cell Disease.
Where Crizanlizumab is approved
All regulators →Of the three regulators tracked here, the first to approve Crizanlizumab was the US, on 15 Nov 2019.
- 2 EU safety letters (DHPC), latest: lack of effect;referral - article 20 procedure for Adakveo, 15 Jun 2023
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Crizanlizumab
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Crizanlizumab works
All drug targets →- P-selectin blocker BlockerTarget: SELP selectin P✓ In ChEMBL and the Guide to Pharmacology
- COVID-19Phase 2
- PriapismPhase 2
- Chronic kidney diseasePhase 2
- GlioblastomaPhase 2
- MelanomaPhase 2
- Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestationsPhase 2
- MyelofibrosisPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297734, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 10550, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Crizanlizumab
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Crizanlizumab. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Crizanlizumab for preventing sickle cell crises in sickle cell disease NICE TA743 | Optimised | 3 Nov 2021 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Crizanlizumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Crizanlizumab
4 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Crizanlizumab
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
| Sheba Medical Center | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Crizanlizumab trials
How many clinical trials are testing Crizanlizumab?
4 current trials in our USA, Brazil, Germany, France, Spain, Italy, Belgium, Turkey, UK, India, Netherlands, Canada and Israel registers name Crizanlizumab (also registered as SEG101) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Crizanlizumab trials recruiting patients?
Yes. 3 of the 4 trials are recruiting: 2 with sites in USA, 2 with sites in Brazil, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Turkey and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Crizanlizumab clinical trials?
Novartis Pharmaceuticals (3) and Sheba Medical Center (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Crizanlizumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Crizanlizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Crizanlizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.